Bausch + Lomb Secures Additional Approvals of Vyzulta in Hong Kong and Argentina
01/16/2020
Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution) 0.024% in Hong Kong and Argentina.
With these approvals, Vyzulta is now approved for commercialization in a total of five countries and territories. Vyzulta is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension.
Nicox receives increasing tiered net royalties of 6% to 12% on global sales of Vyzulta as well as up to $150 million in potential future milestones.